An early study into ROR1 protein expression across a range of tumour types reported “moderate” or “high” expression in 83% of pancreatic cancer samples (n = 48) using the high-affinity 4A5 monoclonal antibody against ROR1 [25]. This evidence concerns the gene ROR1 and pancreatic neoplasm.